Uncommon Cents Investing LLC Sells 755 Shares of Fresenius Medical Care AG (NYSE:FMS)

Uncommon Cents Investing LLC lessened its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 1.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 40,625 shares of the company’s stock after selling 755 shares during the period. Uncommon Cents Investing LLC’s holdings in Fresenius Medical Care were worth $920,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of FMS. Franklin Street Advisors Inc. NC purchased a new position in Fresenius Medical Care during the 4th quarter worth $201,000. GAMMA Investing LLC increased its stake in shares of Fresenius Medical Care by 43.3% during the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock valued at $162,000 after buying an additional 2,166 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Fresenius Medical Care by 18.2% in the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock valued at $211,000 after acquiring an additional 1,528 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock valued at $1,490,000 after acquiring an additional 2,386 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Fresenius Medical Care in the third quarter worth about $38,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on FMS shares. Truist Financial boosted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. Berenberg Bank began coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective on the stock. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Finally, StockNews.com assumed coverage on Fresenius Medical Care in a report on Friday, January 3rd. They issued a “strong-buy” rating on the stock.

Fresenius Medical Care Stock Down 0.3 %

NYSE:FMS opened at $23.09 on Monday. The company’s 50-day simple moving average is $22.70 and its 200-day simple moving average is $20.90. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $24.31. The stock has a market capitalization of $13.55 billion, a P/E ratio of 19.08, a P/E/G ratio of 0.72 and a beta of 0.92.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.